JP2010524432A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010524432A5 JP2010524432A5 JP2009554564A JP2009554564A JP2010524432A5 JP 2010524432 A5 JP2010524432 A5 JP 2010524432A5 JP 2009554564 A JP2009554564 A JP 2009554564A JP 2009554564 A JP2009554564 A JP 2009554564A JP 2010524432 A5 JP2010524432 A5 JP 2010524432A5
- Authority
- JP
- Japan
- Prior art keywords
- sirtuin
- subject
- biomarkers
- item
- increased
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000011990 Sirtuin Human genes 0.000 claims description 159
- 108050002485 Sirtuin Proteins 0.000 claims description 159
- 238000000034 method Methods 0.000 claims description 124
- 239000000090 biomarker Substances 0.000 claims description 104
- 150000001875 compounds Chemical class 0.000 claims description 33
- 239000012472 biological sample Substances 0.000 claims description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 claims description 22
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 claims description 22
- 208000035475 disorder Diseases 0.000 claims description 16
- 101710200896 Acyl-CoA thioesterase 2 Proteins 0.000 claims description 15
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 claims description 15
- 101710134520 Acyl-coenzyme A thioesterase 2, mitochondrial Proteins 0.000 claims description 15
- 102100025851 Acyl-coenzyme A thioesterase 2, mitochondrial Human genes 0.000 claims description 15
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims description 15
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims description 15
- 102000018616 Apolipoproteins B Human genes 0.000 claims description 15
- 108010027006 Apolipoproteins B Proteins 0.000 claims description 15
- 102000013918 Apolipoproteins E Human genes 0.000 claims description 15
- 108010025628 Apolipoproteins E Proteins 0.000 claims description 15
- 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 claims description 15
- 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 claims description 15
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 claims description 15
- 102100034871 C-C motif chemokine 8 Human genes 0.000 claims description 15
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims description 15
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 claims description 15
- 101000946794 Homo sapiens C-C motif chemokine 8 Proteins 0.000 claims description 15
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 claims description 15
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 15
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims description 15
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 15
- 101100191094 Mus musculus Ppp1r3g gene Proteins 0.000 claims description 15
- 108010071690 Prealbumin Proteins 0.000 claims description 15
- 101150105133 RRAD gene Proteins 0.000 claims description 15
- 102000009190 Transthyretin Human genes 0.000 claims description 15
- 101710175445 Acyl-coenzyme A thioesterase 1 Proteins 0.000 claims description 14
- 102100025854 Acyl-coenzyme A thioesterase 1 Human genes 0.000 claims description 14
- 108010087614 Apolipoprotein A-II Proteins 0.000 claims description 14
- 102000009081 Apolipoprotein A-II Human genes 0.000 claims description 14
- 102000012002 Aquaporin 4 Human genes 0.000 claims description 14
- 108010036280 Aquaporin 4 Proteins 0.000 claims description 14
- 101710137710 Thioesterase 1/protease 1/lysophospholipase L1 Proteins 0.000 claims description 14
- 102100026745 Fatty acid-binding protein, liver Human genes 0.000 claims description 13
- 101000911317 Homo sapiens Fatty acid-binding protein, liver Proteins 0.000 claims description 13
- 101150028244 Smpdl3a gene Proteins 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- 230000001225 therapeutic effect Effects 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 11
- 238000012544 monitoring process Methods 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 8
- 230000001404 mediated effect Effects 0.000 claims description 8
- 201000001119 neuropathy Diseases 0.000 claims description 8
- 230000007823 neuropathy Effects 0.000 claims description 8
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 8
- 230000004913 activation Effects 0.000 claims description 7
- 108020004999 messenger RNA Proteins 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 230000003213 activating effect Effects 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 230000032683 aging Effects 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 208000015294 blood coagulation disease Diseases 0.000 claims description 4
- 238000002512 chemotherapy Methods 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 208000030533 eye disease Diseases 0.000 claims description 4
- 238000011010 flushing procedure Methods 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 230000000302 ischemic effect Effects 0.000 claims description 4
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 230000035882 stress Effects 0.000 claims description 4
- 102000000344 Sirtuin 1 Human genes 0.000 claims description 3
- 108010041191 Sirtuin 1 Proteins 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 claims description 3
- 210000004209 hair Anatomy 0.000 claims description 3
- 238000002493 microarray Methods 0.000 claims description 3
- 210000002381 plasma Anatomy 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims 17
- 239000012190 activator Substances 0.000 claims 5
- 108700012920 TNF Proteins 0.000 claims 3
- 101100226589 Mus musculus Fabp1 gene Proteins 0.000 claims 2
- 238000005259 measurement Methods 0.000 claims 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 102000005488 Thioesterase Human genes 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 108020002982 thioesterase Proteins 0.000 claims 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 21
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 21
- LAMQVIQMVKWXOC-UHFFFAOYSA-N 4-methyl-n-[2-[3-(morpholin-4-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]-2-pyridin-3-yl-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C=2C=NC=CC=2)SC=1C(=O)NC1=CC=CC=C1C(N=C1SC=2)=CN1C=2CN1CCOCC1 LAMQVIQMVKWXOC-UHFFFAOYSA-N 0.000 description 15
- 230000007943 positive regulation of appetite Effects 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 229940078753 Sirtuin inhibitor Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91873507P | 2007-03-19 | 2007-03-19 | |
| PCT/US2008/003605 WO2008115518A2 (en) | 2007-03-19 | 2008-03-19 | Biomarkers of sirtuin activity and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010524432A JP2010524432A (ja) | 2010-07-22 |
| JP2010524432A5 true JP2010524432A5 (enExample) | 2011-05-06 |
Family
ID=39708658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009554564A Pending JP2010524432A (ja) | 2007-03-19 | 2008-03-19 | サーチュイン活性のバイオマーカーおよびその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20100215632A1 (enExample) |
| EP (1) | EP2126109A2 (enExample) |
| JP (1) | JP2010524432A (enExample) |
| AU (1) | AU2008229385A1 (enExample) |
| CA (1) | CA2680823A1 (enExample) |
| WO (1) | WO2008115518A2 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
| US11207518B2 (en) * | 2004-12-27 | 2021-12-28 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway |
| ES2389111T3 (es) * | 2005-12-02 | 2012-10-23 | Sirtris Pharmaceuticals, Inc. | Ensayos de espectrometría de masas para la actividad acetiltransferasa/desacetilasa |
| US8391970B2 (en) * | 2007-08-27 | 2013-03-05 | The Feinstein Institute For Medical Research | Devices and methods for inhibiting granulocyte activation by neural stimulation |
| WO2009146030A1 (en) | 2008-03-31 | 2009-12-03 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation of t-cell activity |
| US9662490B2 (en) | 2008-03-31 | 2017-05-30 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug |
| EA021938B1 (ru) | 2008-05-01 | 2015-10-30 | Сертрис Фармасьютикалз, Инк. | Хинолины и их аналоги в качестве модуляторов сиртуина |
| KR20110036602A (ko) | 2008-07-03 | 2011-04-07 | 서트리스 파마슈티컬즈, 인코포레이티드 | 시르투인 조절제로서의 벤즈이미다졸 및 관련 유사체 |
| MX349176B (es) | 2008-09-22 | 2017-07-14 | Biochemics Inc | Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo. |
| AU2009295948B2 (en) | 2008-09-29 | 2013-12-05 | GlaxoSmithKline, LLC | Quinazolinone, quinolone and related analogs as sirtuin modulators |
| BRPI0806044A2 (pt) * | 2008-10-17 | 2010-09-14 | União Brasileira De Educação E Assistência - Mantenedora Da Pucrs | método e kit para determinação de agentes moduladores de sirtuìnas, processo para modulação de sirtuìnas, compostos moduladores de sirtuìnas e composições compreendendo os mesmos |
| CN102215909B (zh) | 2008-11-18 | 2014-09-10 | 赛博恩特医疗器械公司 | 优化用于消炎刺激的电极放置的装置和方法 |
| US8996116B2 (en) * | 2009-10-30 | 2015-03-31 | Setpoint Medical Corporation | Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction |
| US8788034B2 (en) | 2011-05-09 | 2014-07-22 | Setpoint Medical Corporation | Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
| US9211410B2 (en) | 2009-05-01 | 2015-12-15 | Setpoint Medical Corporation | Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
| EP2440284B1 (en) | 2009-06-09 | 2018-09-12 | Setpoint Medical Corporation | Nerve cuff with pocket for leadless stimulator |
| WO2011028763A2 (en) * | 2009-09-01 | 2011-03-10 | Setpoint Medical Corporation | Prescription pad for treatment of inflammatory disorders |
| US9556201B2 (en) | 2009-10-29 | 2017-01-31 | Glaxosmithkline Llc | Bicyclic pyridines and analogs as sirtuin modulators |
| US11051744B2 (en) | 2009-11-17 | 2021-07-06 | Setpoint Medical Corporation | Closed-loop vagus nerve stimulation |
| US9833621B2 (en) | 2011-09-23 | 2017-12-05 | Setpoint Medical Corporation | Modulation of sirtuins by vagus nerve stimulation |
| EP2515996B1 (en) | 2009-12-23 | 2019-09-18 | Setpoint Medical Corporation | Neural stimulation devices and systems for treatment of chronic inflammation |
| EP2993236A1 (en) * | 2010-04-15 | 2016-03-09 | Glaxosmithkline LLC | Sirtuin activators and activation assays |
| WO2011139387A1 (en) | 2010-05-03 | 2011-11-10 | Opko Curna, Llc | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
| CN102559850B (zh) * | 2010-12-16 | 2014-03-05 | 益善生物技术股份有限公司 | 一种apoA5基因突变检测特异性引物和液相芯片 |
| US12172017B2 (en) | 2011-05-09 | 2024-12-24 | Setpoint Medical Corporation | Vagus nerve stimulation to treat neurodegenerative disorders |
| WO2013024821A1 (ja) * | 2011-08-12 | 2013-02-21 | 国立大学法人筑波大学 | 並列反応用懸濁液、並列反応方法およびスクリーニング方法 |
| US9572983B2 (en) | 2012-03-26 | 2017-02-21 | Setpoint Medical Corporation | Devices and methods for modulation of bone erosion |
| RU2612630C2 (ru) * | 2014-09-17 | 2017-03-09 | Федеральное бюджетное учреждение науки "Центральный научно-исследовательский институт эпидемиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ЦНИИ Эпидемиологии Роспотребнадзора) | Способ определения индивидуального генетического риска развития ишемического инсульта |
| US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
| US11406833B2 (en) | 2015-02-03 | 2022-08-09 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
| US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
| CN108882885A (zh) | 2016-01-20 | 2018-11-23 | 赛博恩特医疗器械公司 | 迷走神经刺激的控制 |
| US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
| EP3405255B1 (en) | 2016-01-20 | 2025-12-31 | Setpoint Medical Corporation | IMPLANTABLE MICROSTIMULATORS AND INDUCTION CHARGING SYSTEMS |
| US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
| CA3051826A1 (en) * | 2017-01-27 | 2018-08-02 | A-Clip Institute, Co., Ltd. | Prophylactic and/or therapeutic agent for infectious disease or inflammatory disease |
| EP3668402B1 (en) | 2017-08-14 | 2024-07-31 | Setpoint Medical Corporation | Vagus nerve stimulation pre-screening test |
| WO2019109044A1 (en) * | 2017-12-01 | 2019-06-06 | The Scripps Research Institute | Methods and materials for assessing biological age and slowing the progress of excessive biological aging |
| US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
| KR102127903B1 (ko) * | 2019-01-29 | 2020-06-29 | 연세대학교 산학협력단 | 염증성 호흡기 질환의 진단용 바이오마커 |
| US12343535B2 (en) | 2019-04-12 | 2025-07-01 | Setpoint Medical Corporation | Vagus nerve stimulation to treat neurodegenerative disorders |
| EP4090424A4 (en) | 2020-01-13 | 2024-02-21 | The Feinstein Institutes for Medical Research | TREATMENT OF BLEEDING AND BLEEDING DISORDERS BY HIGH-INTENSITY FOCUSED ULTRASONIC STIMULATION OF THE SPLEEN |
| US11938324B2 (en) | 2020-05-21 | 2024-03-26 | The Feinstein Institutes For Medical Research | Systems and methods for vagus nerve stimulation |
| WO2022245878A1 (en) | 2021-05-17 | 2022-11-24 | Setpoint Medical Corporation | Neurostimulation parameter authentication and expiration system for neurostimulation |
| EP4466064A4 (en) | 2022-01-20 | 2026-01-14 | Setpoint Medical Corp | TREATMENT OF INFLAMMATORY DISORDERS |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6716626B1 (en) * | 1999-11-18 | 2004-04-06 | Chiron Corporation | Human FGF-21 nucleic acids |
| WO2008060400A2 (en) * | 2006-11-15 | 2008-05-22 | Sirtris Pharmaceuticals, Inc. | Sirtuin polymorphisms and methods of use thereof |
| US20100168084A1 (en) * | 2008-05-08 | 2010-07-01 | Huber L Julie | Therapeutic compounds and related methods of use |
-
2008
- 2008-03-19 JP JP2009554564A patent/JP2010524432A/ja active Pending
- 2008-03-19 EP EP08726980A patent/EP2126109A2/en not_active Ceased
- 2008-03-19 WO PCT/US2008/003605 patent/WO2008115518A2/en not_active Ceased
- 2008-03-19 CA CA002680823A patent/CA2680823A1/en not_active Abandoned
- 2008-03-19 US US12/450,252 patent/US20100215632A1/en not_active Abandoned
- 2008-03-19 AU AU2008229385A patent/AU2008229385A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schwartz | Marrow fat and bone: review of clinical findings | |
| Muñoz | Diagnosis of chronic pancreatitis: Functional testing | |
| Dalmas et al. | Irf5 deficiency in macrophages promotes beneficial adipose tissue expansion and insulin sensitivity during obesity | |
| Murugesan et al. | Brain regional angiogenic potential at the neurovascular unit during normal aging | |
| Araki et al. | TDP-43 regulates early-phase insulin secretion via CaV1. 2-mediated exocytosis in islets | |
| Brettschneider et al. | Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis | |
| Janghra et al. | Correlation of utrophin levels with the dystrophin protein complex and muscle fibre regeneration in Duchenne and Becker muscular dystrophy muscle biopsies | |
| O’Hara et al. | Methods for detecting toxic α-synuclein species as a biomarker for Parkinson’s disease | |
| Pelisek et al. | Neovascularization and angiogenic factors in advanced human carotid artery stenosis | |
| RU2014112348A (ru) | Способ детекции нуклеосом, содержащих гистоновые варианты | |
| Xue et al. | Clinical significance of changes in serum neuroglobin and HIF-1α concentrations during the early-phase of acute ischemic stroke | |
| JP2016533499A5 (enExample) | ||
| Bettini et al. | Resting energy expenditure, insulin resistance and UCP1 expression in human subcutaneous and visceral adipose tissue of patients with obesity | |
| WO2011094535A2 (en) | Biomarkers of aging for detection and treatment of disorders | |
| JP2010539508A5 (enExample) | ||
| KR20100059902A (ko) | 질병의 발달을 모니터링하고 치료의 효율을 평가하기 위한 새로운 바이오마커 | |
| Cai et al. | Predictive value of phosphorylated axonal neurofilament subunit H for clinical outcome in patients with acute intracerebral hemorrhage | |
| CN101578376A (zh) | 诊断和治疗炎性应答的方法 | |
| Batchu et al. | Lung and kidney ACE2 and TMPRSS2 in renin-angiotensin system blocker–treated comorbid diabetic mice mimicking host factors that have been linked to severe COVID-19 | |
| JP2008536480A5 (enExample) | ||
| JP2006502203A5 (enExample) | ||
| St-Pierre et al. | Association between nesfatin-1 levels and metabolic improvements in severely obese patients who underwent biliopancreatic derivation with duodenal switch | |
| Hirose et al. | Increased expression of (pro) renin receptor in the remnant kidneys of 5/6 nephrectomized rats | |
| Estep et al. | Non-invasive diagnostic tests for non-alcoholic fatty liver disease | |
| JP2019510974A5 (enExample) |